Goodwin advised Life Edit Therapeutics on the deal. Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company, announced a research and development collaboration to discover and...
You must be a Standard 1 Year member to access this content.
Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
You must be a Standard 1 Year member to access this content.
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Sichuan Kelun-Biotech Biopharmaceutical Co. on the deal. Sichuan Kelun-Biotech Biopharmaceutical Co. announced its exclusive license and collaboration agreement with Merck for ex-China development...
You must be a Standard 1 Year member to access this content.
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz and Willkie Farr & Gallagher advised Constellation on the deal. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...
You must be a Standard 1 Year member to access this content.
